These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15507522)

  • 1. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532.
    El-Daly H; Kull M; Zimmermann S; Pantic M; Waller CF; Martens UM
    Blood; 2005 Feb; 105(4):1742-9. PubMed ID: 15507522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
    Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
    Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
    Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death.
    Liu R; Liu J; Wang S; Wang Y; Zhang T; Liu Y; Geng X; Wang F
    Cell Death Dis; 2019 Jul; 10(7):527. PubMed ID: 31296842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of telomerase using BIBR1532 enhances doxorubicin-induced apoptosis in pre-B acute lymphoblastic leukemia cells.
    Bashash D; Zareii M; Safaroghli-Azar A; Omrani MD; Ghaffari SH
    Hematology; 2017 Jul; 22(6):330-340. PubMed ID: 28054503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies.
    Biray Avci C; Dogan F; Ozates Ay NP; Goker Bagca B; Abbaszadeh Z; Gunduz C
    J Cell Biochem; 2018 Dec; 119(12):9817-9824. PubMed ID: 30145821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.
    Shi Y; Sun L; Chen G; Zheng D; Li L; Wei W
    Target Oncol; 2015 Dec; 10(4):565-73. PubMed ID: 25916999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.
    Bashash D; Ghaffari SH; Mirzaee R; Alimoghaddam K; Ghavamzadeh A
    Leuk Lymphoma; 2013 Mar; 54(3):561-8. PubMed ID: 22957790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
    Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
    Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
    Ward RJ; Autexier C
    Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase activity in normal leukocytes and in hematologic malignancies.
    Counter CM; Gupta J; Harley CB; Leber B; Bacchetti S
    Blood; 1995 May; 85(9):2315-20. PubMed ID: 7727765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
    Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
    Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase inhibition on acute myeloid leukemia stem cell induced apoptosis with both intrinsic and extrinsic pathways.
    Rafat A; Dizaji Asl K; Mazloumi Z; Movassaghpour AA; Talebi M; Shanehbandi D; Farahzadi R; Nejati B; Nozad Charoudeh H
    Life Sci; 2022 Apr; 295():120402. PubMed ID: 35176279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
    Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
    Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line.
    Pourbagheri-Sigaroodi A; Bashash D; Safaroghli-Azar A; Farshi-Paraasghari M; Momeny M; Mansoor FN; Ghaffari SH
    Eur J Pharmacol; 2019 Mar; 846():49-62. PubMed ID: 30658112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia.
    Sumi M; Tauchi T; Sashida G; Nakajima A; Gotoh A; Shin-Ya K; Ohyashiki JH; Ohyashiki K
    Int J Oncol; 2004 Jun; 24(6):1481-7. PubMed ID: 15138591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of compound aITEL1296 on telomerase activity and the growth of cancer cells].
    Kovalenko NA; Zhdanov DD; Bibikova MV; Gotovtseva VIu
    Biomed Khim; 2011; 57(5):501-10. PubMed ID: 22629600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.